查看购物车
  • Traditional Chinese
  • English
  • Japanese
北美疫苗佐剂市场预测至 2030 年 - 区域分析 - 按佐剂类别（矿物盐佐剂、乳液佐剂、脂质体佐剂等）和类型（人用疫苗佐剂和兽用疫苗佐剂）
市场调查报告书
商品编码
1666306

北美疫苗佐剂市场预测至 2030 年 - 区域分析 - 按佐剂类别（矿物盐佐剂、乳液佐剂、脂质体佐剂等）和类型（人用疫苗佐剂和兽用疫苗佐剂）

North America Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
出版日期: | 出版商: The Insight Partners | 英文 88 Pages | 订单完成后即时交付

价格

2022年北美疫苗佐剂市值为10.4484亿美元，预计到2030年将达到28.6204亿美元；预计 2022 年至 2030 年的复合年增长率为 13.4%。

传染病爆发和流行病的不断增加推动了北美疫苗佐剂市场的发展

根据世界银行2023年的报告，细菌、病毒、寄生虫或真菌疾病都具有传染性，可以直接在人与人之间或动物与人之间传播。根据美国国立卫生研究院（NIH）的报告，H1N1流感大流行导致墨西哥旅游业损失约28亿美元，因为在H1N1病毒传染性的5个月内，游客人数减少了近100万人。墨西哥特斯科科州于 2024 年 3 月报告爆发低致病性禽流感 (LPAI) A(H5N2) 疫情，同一州的特马斯卡拉帕市于 4 月报告爆发另一起疫情。此外，在米却肯州，一家私人家禽养殖场发现了高致病性禽流感 A(H5N2) 疫情，该疫情于 2024 年 3 月发现。儘管动物流感病毒通常会感染动物，但它们也可以感染人类。人类的感染大多是透过与受感染的动物或受污染环境的密切接触而感染的。根据原始宿主，甲型流感病毒可分为禽流感、猪流感或其他动物流感病毒。因此，各类传染病的出现及其伴随的成本负担加速了製造商对疫苗和疫苗佐剂的需求。

COVAXIN 是 Bharat Biotech 为对抗新冠疫情而开发的疫苗，使用 Alhydroxiquim-II 作为佐剂。生技公司ViroVax LLC在实验室中发现并测试了这种佐剂。 Alhydroxiquim-II 的药理作用是透过淋巴结并激活 TLR7 和 TLR8 细胞受体，这在对抗病毒的免疫反应中发挥着至关重要的作用。 Alhydroxiquim-II是第一个负责活化TLR7和TLR8的佐剂，进而刺激人体的免疫反应。因此，传染病爆发和大流行的数量不断增加，导致医疗费用高昂，从而推动了对疫苗佐剂的需求。

北美疫苗佐剂市场概况

北美疫苗佐剂市场分为美国、加拿大和墨西哥。快速的产品审批流程有利于美国疫苗佐剂市场。 2023年5月，葛兰素史克（GSK）的Arexvy（呼吸道合胞病毒疫苗，佐剂型）疫苗获得美国食品药物管理局（FDA）核准，用于预防呼吸道合胞病毒（RSV）引起的下呼吸道疾病（LRTD）。因此，Arexvy 成为全球首个获得 FDA 批准的老年人 RSV 疫苗。 2022 年 10 月，Novavax, Inc. 的 COVID-19 佐剂疫苗获得 FDA 紧急使用授权 (EUA)，用于成年患者的加强剂。

北美疫苗佐剂市场收入及 2030 年预测（百万美元）

北美疫苗佐剂市场区隔

北美疫苗佐剂市场分为佐剂类别、类型和国家。

依佐剂类别，北美疫苗佐剂市场分为矿物盐佐剂、乳液佐剂、脂质体佐剂等。 2022 年，矿物盐佐剂占据北美疫苗佐剂市场的最大份额。

根据类型，北美疫苗佐剂市场分为人用疫苗佐剂和兽用疫苗佐剂。 2022 年，人类疫苗佐剂部分占据了北美疫苗佐剂市场的较大份额。

依国家划分，北美疫苗佐剂市场分为美国、加拿大和墨西哥。 2022 年，美国占据北美疫苗佐剂市场的主导份额。

Croda International Plc； CSL有限公司； Dynavax Technologies Corp；葛兰素史克公司；夏威夷生物技术公司； InvivoGen SAS； Novavax Inc； Phibro 动物健康公司；塞皮克 SA；和 SPI Pharma Inc 是北美疫苗佐剂市场的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美疫苗佐剂市场 - 主要市场动态

  • 北美疫苗佐剂市场 - 主要市场动态
  • 市场驱动因素
    • 传染病爆发和疫情数量不断增加
    • 兽用疫苗佐剂的核准
  • 市场限制
    • 产品召回和不良影响
  • 市场机会
    • 支持辅助研究的发展和产品发布的合作努力
    • 生物技术和免疫学的进展
  • 未来趋势
    • 技术进步
  • 驱动因素和限制因素的影响：

第 5 章：疫苗佐剂市场 - 北美分析

  • 北美疫苗佐剂市场 - 收入及 2030 年预测
  • 北美疫苗佐剂市场预测与分析

第 6 章：北美疫苗佐剂市场分析 - 按佐剂类别

  • 概述
  • 矿物盐佐剂
  • 乳化助剂
  • 脂质体佐剂
  • 其他的

第 7 章：北美疫苗佐剂市场分析 - 按类型

  • 人类疫苗佐剂
  • 兽用疫苗佐剂

第 8 章：北美疫苗佐剂市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第九章：产业格局

  • 概述
  • 全球疫苗佐剂市场的成长策略
  • 有机发展
    • 概述
  • 无机发展
    • 概述

第十章：公司简介

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Hawaii Biotech Inc
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第 11 章：附录

Product Code: BMIRE00031087

The North America vaccine adjuvants market was valued at US$ 1,044.84 million in 2022 and is expected to reach US$ 2,862.04 million by 2030; it is estimated to register a CAGR of 13.4% from 2022 to 2030 .

Rising Number of Infectious Disease Outbreaks and Pandemic Fuels North America Vaccine Adjuvants Market

According to the World Bank 2023 report, bacterial, viral, parasite, or fungal diseases can be contagious, spreading directly from person to person or animal to person. As per the National Institute of Health (NIH) report, the H1N1 influenza pandemic resulted in losses of ~US$ 2.8 billion to the Mexican tourism industry, as the footfall of tourists decreased by nearly 1 million over a 5-month window of the contagious spread of H1N1 virus. The Mexican state of Texcoco reported an outbreak of low pathogenicity avian influenza (LPAI) A(H5N2) in March 2024, and Temascalapa municipality in the same state reported another outbreak in April. Additionally, in the state of Michoacan, a private poultry farm detected a high-pathogenicity avian influenza A(H5N2) outbreak that was discovered in March 2024. In 2022, it was reported that both LPAI and HPAI A(H5) subtypes have been found in bird species in Mexico, both recently and in the past. Although they typically infect animals, animal influenza viruses can also infect people. Human infections have mostly been contracted via close contact with animals that are infected or contaminated environments. Influenza A viruses can be categorized as avian influenza, swine influenza, or other animal influenza viruses based on their original host. Therefore, the emergence of various infectious diseases with the associated cost burden accelerates the manufacturers' demand for vaccines and vaccine adjuvants.

COVAXIN, a vaccine developed by Bharat Biotech to fight against the COVID-19 pandemic, uses Alhydroxiquim-II as an adjuvant. The biotech company ViroVax LLC discovered and tested this adjuvant in the laboratory. The pharmacological action of Alhydroxiquim-II is that it travels through lymph nodes and activates TLR7 and TLR8 cellular receptors, which play a vital role in the immune response against viruses. Alhydroxiquim-II is the first adjuvant responsible for activating TLR7 and TLR8, thus stimulating people's immune responses. Therefore, the rising number of infectious disease outbreaks and pandemics, accounting for high healthcare costs, propels the demand for vaccine adjuvants.

North America Vaccine Adjuvants Market Overview

The North America vaccine adjuvants market has been segmented into the US, Canada, and Mexico. Fast product approval processes benefit the vaccine adjuvants market in the US. In May 2023, GlaxoSmithKline (GSK) won US Food and Drug Administration (FDA) approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) vaccine intended for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Thus, Arexvy became the world's first FDA-approved RSV vaccine for older adults. In October 2022, Novavax, Inc. received an Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, indicated as a booster for adult patients.

North America Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

North America Vaccine Adjuvants Market Segmentation

The North America vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the North America vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the North America vaccine adjuvants market share in 2022.

By type, the North America vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of North America vaccine adjuvants market in 2022.

By country, the North America vaccine adjuvants market is segmented into the US, Canada, and Mexico. The US dominated the North America vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the North America vaccine adjuvants market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Vaccine Adjuvants Market - Key Market Dynamics

  • 4.1 North America Vaccine Adjuvants Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 4.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls and Adverse Effects
  • 4.4 Market Opportunities
    • 4.4.1 Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches
    • 4.4.2 Advancements in Biotechnology and Immunology
  • 4.5 Future Trends
    • 4.5.1 Technological Advancements
  • 4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -North America Analysis

  • 5.1 North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 5.2 North America Vaccine Adjuvants Market Forecast and Analysis

6. North America Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 6.1 Overview
  • 6.2 Mineral Salt Adjuvant
    • 6.2.1 Overview
    • 6.2.2 Mineral Salt Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Emulsion Adjuvant
    • 6.3.1 Overview
    • 6.3.2 Emulsion Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Liposome Adjuvant
    • 6.4.1 Overview
    • 6.4.2 Liposome Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Vaccine Adjuvants Market Analysis - by Type

  • 7.1 Human Vaccine Adjuvant
    • 7.1.1 Overview
    • 7.1.2 Human Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Veterinary Vaccine Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Veterinary Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Vaccine Adjuvants Market -Country Analysis

  • 8.1 North America
    • 8.1.1 North America Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 8.1.1.1 United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.1 Overview
        • 8.1.1.1.2 United States: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.3 United States: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.1.4 United States: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.1 Overview
        • 8.1.1.2.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.3 Canada: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.2.4 Canada: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.3 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.1 Overview
        • 8.1.1.3.2 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.3 Mexico: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.3.4 Mexico: Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Global Vaccine Adjuvants Market
  • 9.3 Organic Developments
    • 9.3.1 Overview
  • 9.4 Inorganic Developments
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 SPI Pharma Inc
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 GSK Plc
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 CSL Ltd
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Seppic SA
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Hawaii Biotech Inc
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Dynavax Technologies Corp
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 InvivoGen SAS
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Croda International Plc
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 Novavax Inc
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments
  • 10.10 Phibro Animal Health Corp
    • 10.10.1 Key Facts
    • 10.10.2 Business Description
    • 10.10.3 Products and Services
    • 10.10.4 Financial Overview
    • 10.10.5 SWOT Analysis
    • 10.10.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners

List Of Tables

  • Table 1. North America Vaccine Adjuvants Market Segmentation
  • Table 2. North America Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
  • Table 3. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 4. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 5. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 6. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 8. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 9. Organic Developments Done by Companies
  • Table 10. Inorganic Developments Done by Companies

List Of Figures

  • Figure 1. North America Vaccine Adjuvants Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 4. North America Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 5. Mineral Salt Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Emulsion Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Liposome Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 10. Human Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Veterinary Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. North America Vaccine Adjuvants Market by Key Countries - Revenue (2022) US$ Million
  • Figure 13. North America Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 14. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 15. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 16. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 17. Growth Strategies in the Vaccine Adjuvants Market